| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5422123 (Pediatric) | APOTEX | Tablets with controlled-rate release of active substances |
Dec, 2012
(11 years ago) | |
| US6133289 | APOTEX | Paroxetine hydrochloride form A or C |
May, 2015
(8 years ago) | |
| US5900423 | APOTEX | Form of paroxetine hydrochloride anhydrate |
May, 2015
(8 years ago) | |
| US5872132 | APOTEX | Form of paroxetine hydrochloride anhydrate |
May, 2015
(8 years ago) | |
|
US5872132 (Pediatric) | APOTEX | Form of paroxetine hydrochloride anhydrate |
Nov, 2015
(8 years ago) | |
|
US5900423 (Pediatric) | APOTEX | Form of paroxetine hydrochloride anhydrate |
Nov, 2015
(8 years ago) | |
|
US6133289 (Pediatric) | APOTEX | Paroxetine hydrochloride form A or C |
Nov, 2015
(8 years ago) | |
| US7229640 | APOTEX | Paroxetine controlled release compositions |
Jul, 2016
(7 years ago) | |
| US6548084 | APOTEX | Controlled release compositions |
Jul, 2016
(7 years ago) | |
|
US6548084 (Pediatric) | APOTEX | Controlled release compositions |
Jan, 2017
(7 years ago) | |
|
US7229640 (Pediatric) | APOTEX | Paroxetine controlled release compositions |
Jan, 2017
(7 years ago) | |
| US6121291 | APOTEX | Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder |
Mar, 2017
(7 years ago) | |
|
US6121291 (Pediatric) | APOTEX | Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder |
Sep, 2017
(6 years ago) | |
Paxil Cr is owned by Apotex.
Paxil Cr contains Paroxetine Hydrochloride.
Paxil Cr has a total of 13 drug patents out of which 13 drug patents have expired.
Expired drug patents of Paxil Cr are:
- US5422123*PED
- US6133289
- US5900423
- US5872132
- US5872132*PED
- US5900423*PED
- US6133289*PED
- US7229640
- US6548084
- US6548084*PED
- US7229640*PED
- US6121291
- US6121291*PED
Paxil Cr was authorised for market use on 16 February, 1999.
Paxil Cr is available in tablet, extended release;oral dosage forms.
Paxil Cr can be used as depression, panic disorder, premenstrual disorders and social anxiety disorder, depression.
The generics of Paxil Cr are possible to be released after 17 September, 2017.
Drugs and Companies using PAROXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 1999
Treatment: Depression; Depression, panic disorder, premenstrual disorders and social anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
PAXIL CR family patents
